Malaria Information and Prophylaxis, by Country [I]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Iceland None Not Applicable Not Applicable Not Applicable
India All areas throughout country, including cities of Bombay (Mumbai) and New Delhi, except none in areas > 2,000 m (6,562 ft) in Himachal Pradesh, Jammu and Kashmir, and Sikkim. Chloroquine P. vivax 50%,

P. falciparum >40%,

P. malariae and P. ovale rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Indonesia All areas of eastern Indonesia (provinces of Maluku, North Maluku, East Nusa Tenggara, Papua, and West Papua), including the town of Labuan Bajo and Komodo Islands in the Nusa Tengarra region. Rural areas of Kalimantan (Borneo), West Nusa Tenggara (includes the island of Lombok), Sulawesi, and Sumatra.

Low transmission in rural areas of Java, including Pangandaran, Sukabumi, and Ujung Kulong.

None in the cities of Jakarta and Ubud, resort areas of Bali and Java, the Gili Islands and the Thousand Islands (Pulau Seribu).

Chloroquine (P. falciparum and P. vivax) P. falciparum 60%, P. vivax 40%,
P. knowlesi,7 

P. malariae,
P. ovale
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Iran No indigenous cases reported since 2017. Previously, March-November in rural areas of Fars Province, Sistan-Baluchestan Province, and southern, tropical parts of Hormozgan and Kerman Provinces. Previously, chloroquine Previously, P. vivax 93% and

P. falciparum 7%

None (mosquito avoidance only)6
Iraq None Not Applicable Not Applicable Not Applicable
Ireland None Not Applicable Not Applicable Not Applicable
Israel None Not Applicable Not Applicable Not Applicable
Italy including Holy See (Vatican City) None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2.  Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see:
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.